Ciro Improta, MD

Michael Holmes presents wall shaking data showing in vivo gene therapy using #Tessera gene writers to cure sickle cell disease and create CARs directly in vivo in model systems #Tandem25

Methodological Considerations on How to Identify Human Hematopoietic Stem Cells The hematopoietic system is highly regenerative and is organized hierarchically with hematopoietic stem cells (HSCs) sitting at the apex. Despite being some of the most widely studied stem cells, ques...

If you are approaching human hematopoiesis, this is a great resource for preparing your experimental protocols! Congrats to the authors! @isehsociety.bsky.social
#hemesky 🔬🩸

www.exphem.org/article/S030...

Randomizing the human genome by engineering recombination between repeat elements We lack tools to edit DNA sequences at scales necessary to study 99% of the human genome that is noncoding. To address this gap, we applied CRISPR prime editing to insert recombination handles into re...

We're delighted to share our work on scrambling the human genome using prime editing, repetitive elements, and recombinases in @science.org , led by @jonaskoeppel.bsky.social , @f-raphael.bsky.social , with @proftomellis.bsky.social and George Church.
www.science.org/doi/10.1126/...

Tailoring capsid directed evolution technology for improved AAV-mediated CAR-T generation Westhaus and colleagues developed a new bioengineering platform that allows identification of novel AAV variants that enhance gene editing applications and have validated the platform in human T cells. The new ‘recombinogenic’ AAV variants improve the efficiency of on-target editing and lead to the generation of highly functional CAR T-cells.

Exciting progress in CAR-T therapy! A novel AAV capsid evolution platform identified AAV-T1 and AAV-T2, achieving a 5x improvement in CAR integration at the TRAC locus in T-cells. This enables lower vector doses and more potent T-cells against brain tumors
#CART #CAR-T
www.cell.com/molecular-th...

Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma Abstract. Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immune suppression. Dynamics of immune reconstitution (IR) and impacts of IR on outcomes follow...

#bluetoirial courtesy of @mskcancercenter.bsky.social Roni Shouval Now out in #BloodCancerDiscovery Comprehensive study (n=263) on immune reconstitution after CD19 #CARTcells (axi/liso/tisa-cel) in LBCL. Led by the talented
@DannyLuan6 #Lymphoma #NKcells #lymsm 1/6
aacrjournals.org/bloodcancerd...

Revolutionizing RNA Therapy: Orna Therapeutics' Innovative panCAR™ Approach Unveiled at ASH 2024 Orna Therapeutics showcased groundbreaking data at ASH 2024, highlighting its panCAR™ platform's effectiveness in delivering RNA for B cell-mediated diseases, promising new treatment pathways.

Revolutionizing RNA Therapy: Orna Therapeutics' Innovative panCAR™ Approach Unveiled at ASH 2024 #United_States #San_Diego #Orna_Therapeutics #panCAR™ #RNA_Delivery

Excited to share our new paper @genomeresearch.bsky.social about PlatinumCRISPr thanks to @ihaussmann.bsky.social, @roliarnold.bsky.social, @davidmcquarrie.bsky.social & team.

sgRNA folding matters - our online tool PlatinumCRISPr selects correctly folded sgRNAs.

genome.cshlp.org/content/earl...

SNIPR: modular receptors for safer CAR T-cells and synthetic cell communication. A leap forward in synthetic biology. #CAR-T #Cancer #syntheticbiology

www.nature.com/articles/s41...